{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:58:08Z","timestamp":1785164288942,"version":"3.55.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032226","name":"Parkinson Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178031","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:26:08Z","timestamp":1754421968000},"page":"178031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effect of the mGlu2 receptor positive allosteric modulator AZD8529 on L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset"],"prefix":"10.1016","volume":"1005","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-4721","authenticated-orcid":false,"given":"Judy","family":"Shaqfah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-0215","authenticated-orcid":false,"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-6752","authenticated-orcid":false,"given":"Adjia","family":"Hamadjida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-1522","authenticated-orcid":false,"given":"Fleur","family":"Gaudette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5403-7333","authenticated-orcid":false,"given":"Francis","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-8334","authenticated-orcid":false,"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178031_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00213-016-4501-9","article-title":"From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders","volume":"234","author":"Acri","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-L","article-title":"Functional architecture of basal ganglia circuits: neural substrates of parallel processing","volume":"13","author":"Alexander","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","article-title":"Parallel organization of functionally segregated circuits linking basal ganglia and cortex","volume":"9","author":"Alexander","year":"1986","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0165-0173(98)00050-2","article-title":"Metabotropic glutamate receptors: electrophysiological properties and role in plasticity","volume":"29","author":"Anwyl","year":"1999","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.ejphar.2025.178031_bib5","series-title":"First Time into Man Study to Assess the Safety, Tolerability, and PK of AZD8529 in Healthy Subjects Part B: A Randomized, Open Label Study to Assess the Effect of Food on AZD 8529","article-title":"Phase I, single-center, randomized, double-blind, placebo controlled single-ascending dose","year":"2008"},{"key":"10.1016\/j.ejphar.2025.178031_bib6","series-title":"Pharmacokinetics and Pharmacodynamics of AZD8529 when Given as Single and Multiple Ascending Oral Doses in Healthy Subjects","article-title":"A phase I, single-center, randomized, double-blind, placebo-controlled, study to assess the safety, tolerability","year":"2008"},{"key":"10.1016\/j.ejphar.2025.178031_bib7","series-title":"Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD8529 in Healthy Male Japanese Subjects","article-title":"A phase I, single-centre, randomised, double-blind, placebo controlled single-ascending dose","year":"2009"},{"key":"10.1016\/j.ejphar.2025.178031_bib8","series-title":"Tolerability, and Pharmacokinetics of AZD8529 in Adult Schizophrenia Patients","article-title":"A phase IIa, double-blind, double-dummy, placebo-controlled, active-controlled, randomized, parallel-group study to assess the efficacy, safety","year":"2009"},{"key":"10.1016\/j.ejphar.2025.178031_bib9","series-title":"AZD8529] upon Ketamine-Induced Cortical Stimulation and Impairment of Working-Memory Related Activation of the Prefrontal Cortex","article-title":"A single center, double-blind, randomized, double dummy, placebo-controlled, three-period crossover study to assess the effects of a mGluR2\/3 positive allosteric modulator","year":"2009"},{"key":"10.1016\/j.ejphar.2025.178031_bib10","series-title":"Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms with AZD8529 in Patients with Schizophrenia","article-title":"A single center, double-blind, randomized, placebo-controlled","year":"2009"},{"key":"10.1016\/j.ejphar.2025.178031_bib11","year":"2010"},{"key":"10.1016\/j.ejphar.2025.178031_bib12","series-title":"A Randomised, Open-Label, Three-Way Cross-Over, Phase I Study in Healthy Subjects to Assess the Pharmacokinetics of AZD8329 after Single Doses of the Oral Solid Formulation and the Oral Solution","year":"2010"},{"key":"10.1016\/j.ejphar.2025.178031_bib13","series-title":"AZD8529. Openinnovation","year":"2021"},{"key":"10.1016\/j.ejphar.2025.178031_bib14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00702-020-02247-2","article-title":"The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results","volume":"127","author":"Beaudry","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2025.178031_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2025.178031_bib17","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1471-1931(00)00017-3","article-title":"Electrophysiology of dopamine in normal and denervated striatal neurons","volume":"23","author":"Calabresi","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib18","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S1353-8020(08)70013-0","article-title":"Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits","volume":"13","author":"Calabresi","year":"2007","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.ejphar.2025.178031_sref19","first-page":"S60","article-title":"Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?","volume":"47","author":"Calabresi","year":"2000","journal-title":"Ann. Neurol."},{"issue":"Pt 2","key":"10.1016\/j.ejphar.2025.178031_bib20","first-page":"433","article-title":"Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease","volume":"116","author":"Calabresi","year":"1993","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0166-2236(96)81862-5","article-title":"The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia","volume":"19","author":"Calabresi","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105697","article-title":"Striatal glutamatergic hyperactivity in Parkinson's disease","volume":"168","author":"Campanelli","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2025.178031_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1042\/BST20140006","article-title":"Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease","volume":"42","author":"Cenci","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejphar.2025.178031_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","article-title":"Maladaptive striatal plasticity in L-DOPA-induced dyskinesia","volume":"183","author":"Cenci","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2025.178031_bib25","series-title":"Small Molecule Therapeutics for Schizophrenia","first-page":"101","article-title":"Metabotropic glutamate receptor 2 activators","author":"Cid","year":"2015"},{"key":"10.1016\/j.ejphar.2025.178031_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178031_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.178031_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178031_bib29","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1007\/s12035-024-04644-0","article-title":"EAAT2 activation regulates glutamate excitotoxicity and reduces impulsivity in a rodent model of Parkinson's disease","volume":"62","author":"Das","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.178031_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib31","series-title":"Rowland and Tozer's Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Derendorf","year":"2019"},{"key":"10.1016\/j.ejphar.2025.178031_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"Diederich","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1096\/fj.10-163147","article-title":"A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors","volume":"25","author":"Doumazane","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2025.178031_bib34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib35","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.178031_bib36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"F\u00e9nelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2025.178031_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1463426","article-title":"Clinical and cognitive features associated with psychosis in Parkinson's disease: a longitudinal study","volume":"16","author":"Flanigan","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.178031_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2025.178031_bib40","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","article-title":"Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs","volume":"147","author":"Fribourg","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178031_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","volume":"158","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00221-018-5390-4","article-title":"Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"237","author":"Frouni","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2025.178031_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175429","article-title":"Anti-parkinsonian effect of the mGlu(2) positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset","volume":"939","author":"Frouni","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178031_bib45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00702-020-02287-8","article-title":"Effect of the mGlu(2) positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","volume":"128","author":"Frouni","year":"2021","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2025.178031_bib46","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.clinph.2008.03.017","article-title":"Pathophysiology of parkinsonism","volume":"119","author":"Galvan","year":"2008","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.ejphar.2025.178031_bib47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchromb.2017.07.007","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY\u2010354,740 in rat and marmoset plasma","volume":"1061\u20131062","author":"Gaudette","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejphar.2025.178031_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2018.06.036","article-title":"Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset","volume":"1093\u20131094","author":"Gaudette","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejphar.2025.178031_bib49","series-title":"Handbook of Behavioral Neuroscience","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-374767-9.00001-9","article-title":"Chapter 1 - the neuroanatomical organization of the basal ganglia","author":"Gerfen","year":"2010"},{"key":"10.1016\/j.ejphar.2025.178031_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.178031_bib51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/pr.119.019133","article-title":"International union of basic and clinical pharmacology. CXI. Pharmacology, signaling, and physiology of metabotropic glutamate receptors","volume":"73","author":"Gregory","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2025.178031_bib52","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1460-9568.2006.05047.x","article-title":"Chronic high\u2010frequency stimulation of the subthalamic nucleus and L\u2010DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission","volume":"24","author":"Gubellini","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib53","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00210-018-1549-6","article-title":"Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset","volume":"391","author":"Hamadjida","year":"2018","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejphar.2025.178031_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","article-title":"The highly selective 5-HT(2A) antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset","volume":"139","author":"Hamadjida","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pnpbp.2017.09.001","article-title":"The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset","volume":"81","author":"Hamadjida","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178031_bib56","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00702-017-1830-8","article-title":"Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease","volume":"125","author":"Hamadjida","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2025.178031_bib57","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/ejn.14679","article-title":"The highly selective mGlu(2) receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"51","author":"Hamadjida","year":"2020","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JPD-171134","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 2 study): interim results of an open-label safety study","volume":"7","author":"Hauser","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejphar.2025.178031_bib59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.178031_bib60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.178031_bib61","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","article-title":"The \u03b12\u2010adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti\u2010parkinsonian actions of L\u2010dopa in the MPTP\u2010lesioned primate model of Parkinson's disease","volume":"14","author":"Henry","year":"1999","journal-title":"Mov. Disord.: Official J. Mov. Dis. Soc."},{"key":"10.1016\/j.ejphar.2025.178031_bib62","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","article-title":"Biochemical aspects of Parkinson's disease","volume":"51","author":"Hornykiewicz","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2025.178031_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106452","article-title":"Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice","volume":"193","author":"Huang","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2025.178031_bib64","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.178031_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045587","article-title":"The monoamine Re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset","volume":"7","author":"Huot","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178031_bib66","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib67","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2025.178031_bib68","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-mdma extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib69","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cns.12587","article-title":"The role of group II metabotropic glutamate receptors in the striatum in electroacupuncture treatment of Parkinsonian rats","volume":"23","author":"Jia","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejphar.2025.178031_bib71","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1021\/jm034015u","article-title":"Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2\u2212 trifluoroethylsulfonyl)pyrid-3-ylmethylamine","volume":"46","author":"Johnson","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178031_bib72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib73","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2015.01.014","article-title":"The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys","volume":"78","author":"Justinova","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178031_bib74","doi-asserted-by":"crossref","first-page":"8917","DOI":"10.1007\/s00210-024-03215-3","article-title":"Positive allosteric mGluR2 modulation with BINA alleviates dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset","volume":"397","author":"Kang","year":"2024","journal-title":"N. Schmied. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178031_bib75","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1111\/ejn.16454","article-title":"Effect of the mGlu(2) positive allosteric modulator biphenyl-indanone A as a monotherapy and as adjunct to a low dose of L-DOPA in the MPTP-lesioned marmoset","volume":"60","author":"Kang","year":"2024","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib76","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00210-023-02587-2","article-title":"The mGluR(2\/3) orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","volume":"396","author":"Kang","year":"2023","journal-title":"N. Schmied. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178031_bib77","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00221-018-5434-9","article-title":"5-HT 2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review","volume":"237","author":"Kwan","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2025.178031_bib78","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00210-021-02090-6","article-title":"Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset","volume":"394","author":"Kwan","year":"2021","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejphar.2025.178031_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44869-y","article-title":"Impaired cognitive and motor function are coincident with l-DOPA-induced dyskinesia in a model of Parkinson's disease","volume":"13","author":"Lelos","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178031_bib80","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fnagi.2022.952368","article-title":"Blood neuroexosomal excitatory amino acid transporter-2 is associated with cognitive decline in Parkinson's disease with RBD","volume":"14","author":"Leng","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib81","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2025.178031_bib82","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41598-020-79110-7","article-title":"Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort","volume":"11","author":"Luca","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178031_bib83","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0891-0618(97)00051-3","article-title":"Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites","volume":"13","author":"Luj\u00e1n","year":"1997","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.ejphar.2025.178031_bib84","doi-asserted-by":"crossref","first-page":"8683","DOI":"10.1073\/pnas.93.16.8683","article-title":"The temporal lobe is a target of output from the basal ganglia","volume":"93","author":"Middleton","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2025.178031_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu 5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib86","series-title":"The Study of AZD8529 for Smoking Cessation in Female Smokers","year":"2015"},{"key":"10.1016\/j.ejphar.2025.178031_bib87","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: from the workbench to the bedside","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib88","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L\u2010DOPA administration induces dyskinesias in the 1\u2010methyl\u20104\u2010phenyl\u20101, 2, 3, 6\u2010tetrahydropyridine\u2010treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord.: Official J. Mov. Dis. Soc."},{"key":"10.1016\/j.ejphar.2025.178031_bib89","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","article-title":"Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study","volume":"12","author":"P\u00e9chevis","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib90","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2025.178031_bib91","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA\u2013induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib92","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/brain\/awf269","article-title":"Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment","volume":"125","author":"Picconi","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2025.178031_bib93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrn2379","article-title":"Presynaptic glutamate receptors: physiological functions and mechanisms of action","volume":"9","author":"Pinheiro","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib94","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.clinph.2017.03.043","article-title":"Cortical plasticity and levodopa-induced dyskinesias in Parkinson's disease: connecting the dots in a multicomponent network","volume":"128","author":"Rajan","year":"2017","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.ejphar.2025.178031_bib95","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0306-4522(98)00319-4","article-title":"The basal ganglia: a vertebrate solution to the selection problem?","volume":"89","author":"Redgrave","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2025.178031_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12101286","article-title":"Pimavanserin and Parkinson's disease psychosis: a narrative review","volume":"12","author":"Rissardo","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2025.178031_bib97","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.neuropharm.2007.08.009","article-title":"Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias","volume":"54","author":"Samadi","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.178031_bib98","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","article-title":"Visual hallucinations associated with Parkinson disease","volume":"53","author":"Sanchez-Ramos","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib99","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178031_bib100","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1007\/s00210-024-03627-1","article-title":"The anti-dyskinetic effect of the clinic-ready mGluR(2)positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat","volume":"398","author":"Shaqfah","year":"2025","journal-title":"N. Schmied. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178031_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172957","article-title":"Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","volume":"873","author":"Sid-Otmane","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178031_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1096-9861(19980105)390:1<5::AID-CNE2>3.0.CO;2-6","article-title":"Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2\/3 in the rat basal ganglia","volume":"390","author":"Testa","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib103","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178031_bib104","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.178031_bib105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41398-018-0162-2","article-title":"NMDA antagonists for treating the non-motor symptoms in Parkinson's disease","volume":"8","author":"Vanle","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178031_bib106","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178031_bib107","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/jpet.117.247171","article-title":"Predictive value of parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey","volume":"365","author":"Veyres","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178031_bib108","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.178031_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.614412","article-title":"Circuit mechanisms of L-DOPA-induced dyskinesia (LID)","volume":"15","author":"Yang","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178031_bib110","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1471-4159.2004.02937.x","article-title":"Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes","volume":"92","author":"Yao","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2025.178031_bib111","doi-asserted-by":"crossref","first-page":"e1468","DOI":"10.1212\/WNL.0000000000007189","article-title":"Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD","volume":"92","author":"Yoo","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2025.178031_bib112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0168-0102(91)90097-I","article-title":"The neuronal mechanism underlying parkinsonism and dyskinesia: differential roles of the putamen and caudate nucleus","volume":"12","author":"Yoshida","year":"1991","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejphar.2025.178031_bib113","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500785X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500785X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:51:00Z","timestamp":1772787060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992500785X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":113,"alternative-id":["S001429992500785X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178031","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the mGlu2 receptor positive allosteric modulator AZD8529 on L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178031"}}